Ambulatory Blood Pressure Monitoring, Arterial Stiffness
Conditions
Keywords
olmesartan, chlorthalidone, hemodynamics
Brief summary
The principal aim of the study is to determine whether the hemodynamic parameters measured with the two methods -impedance cardiography and applanation tonometry- can be predictive of the antihypertensive effect of two different classes of drugs, ATII antagonists and diuretics. The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months. The other basic aim of the study is to determine whether there is a difference (\>6mmHg) between the two drugs regarding the reduction of the mean 24hour blood pressure and the effect of them on the hemodynamic parameters. The hemodynamic parameters that will be measured by applanation tonometry are augmentation index, central blood pressure and pulse wave velocity. The hemodynamic parameters that will be measured by impedance cardiography are cardiac index, thoracic fluid content index, systemic vascular resistance index and others.
Detailed description
The principal aim of the study is to determine whether the hemodynamic parameters measured with the two methods -impedance cardiography and applanation tonometry- can be predictive of the antihypertensive effect of two different classes of drugs, ATII antagonists and diuretics. The drugs that will be used in the study are olmesartan and chlorthalidone and the duration of the study is 12 months.
Interventions
DRUGOlmesartan
Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
DRUGChlorthalidone
Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
Sponsors
AHEPA University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Drug naive patients with 1st or 2nd grade Arterial Hypertension according to the ESH/ESC guidelines 2013 * The patient has signed the concent form
Exclusion criteria
* Secondary Hypertension * 3rd grade of Arterial Hypertension * Chronic renal failure * Diabetes Mellitus * Sleep apnea syndrome * Chronic or acute inflammatory diseases * Stroke, myocardial infarction, angina pectoris in the past 6 months * Heart failure * Liver disease * Neoplasms * Pregnancy * Valvular Heart disease * Heigt \< 120cm or \> 230cm, Weight \<30kg or \>155kg * Heart Arrhytmias * Artificial cardiac pacemaker * Hemodymanic unstable patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pulse wave velocity | 12 weeks | Measured by Sphygmocor devive |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systemic vascular resistance | 12 months | Measured by impendance cardiography |
| Ambulatory blood pressure | 12 months | Daytime and nighttime systolic and diastolic blood pressure |
Countries
Greece
Outcome results
None listed